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Summary
 
Chronic inflammatory autoimmune diseases such as multiple sclerosis, diabetes, and rheuma-
toid arthritis are caused by CD4
 
1
 
 Th1 cells. Because Th2 cells antagonize Th1 cell functions in
several ways, it is believed that immune deviation towards Th2 can prevent or cure autoim-
mune diseases. Experimental autoimmune encephalomyelitis (EAE) is a demyelinating disease
used as a model for multiple sclerosis. Using an adoptive transfer system we assessed the role of
Th1 and Th2 cells in EAE. In vitro generated Th1 and Th2 cells from myelin basic protein
(MBP)-specific TCR transgenic mice were transferred into normal and immunodeficient mice.
Th1 cells caused EAE in all recipients after a brief preclinical phase. Surprisingly, Th2 cells also
caused EAE in RAG-1 KO mice and in 
 
ab
 
 T cell–deficient mice, albeit after a longer preclin-
ical phase. Normal or 
 
gd
 
 T cell–deficient mice were resistant to EAE induced by Th2 cells.
The histopathological features of this disease resembled those of an allergic process. In addition,
disease induction by Th1 cells was not altered by coadmininstration of Th2 cells in any of the
recipients. These findings indicate that MBP-specific Th2 cells have the potential to induce
EAE and that the disease induced by previously activated Th1 cells cannot be prevented by
normal lymphocytes nor by previously activated Th2 cells.
 
C
 
D4 T cells can develop into Th1 and Th2 cells char-
acterized by the production of different cytokines;
whereas Th1 cells produce IFN-
 
g
 
, TNF-
 
b
 
, IL-2, and low
levels of IL-10, Th2 cells produce IL-4, IL-5, IL-13, and
high levels of IL-10 (1, 2). Naive T cells can be induced to
differentiate into Th1 effector cells when stimulated in the
presence of IL-12 and into Th2 effector cells when stimu-
lated in the presence of IL-4 (3–5). In addition to the cy-
tokine milieu, a number of other factors have been shown
to influence the differentiation pathway of naive CD4 T
cells, including the affinity of the TCR for the antigen, the
concentration of the antigen, and the type of antigen-pre-
senting cell (reviewed in reference 2). Th1 and Th2 cells
are known to antagonize each other in a variety of ways.
For example, secretion of IL-4 by Th2 cells blocks differ-
entiation of naive cells towards the Th1 pathway. In addi-
tion, production of IL-4, IL-13, and IL-10 by Th2 cells
may suppress many IFN-
 
g
 
–induced macrophage functions.
Conversely, Th1 cells secrete IFN-
 
g
 
, which inhibits the
proliferation of Th2 cells (1, 2).
In chronic inflammatory autoimmune diseases such as
multiple sclerosis (MS)
 
1
 
, diabetes and rheumatoid arthritis,
pathogenic and protective roles have been ascribed to Th1
and Th2 cells, respectively (6–8). Experimental autoim-
mune encephalomyelitis (EAE) is a demyelinating disease
of the central nervous system (CNS) widely used as an ani-
mal model for MS (9). When either Th1 and Th2 cell–
derived cytokines or anti-cytokine blocking antibodies were
administered to animals, the reported effects on the clinical
course of EAE were conflicting. Using an adoptive transfer
model, Racke et al. (10) showed that early treatment with
IL-4 ameliorates EAE. Similarly, Brocke et al. (11) showed
that anti–IL-4 treatment reversed the tolerance induced by
an altered peptide ligand in another EAE adoptive transfer
model. Furthermore, Leonard et al. (12) have shown that
administration of IL-12 increases the severity of EAE,
whereas anti–IL-12 antibodies confer protection in a PLP-
specific adoptive transfer model of EAE. On the other
 
1
 
Abbreviations used in this paper:
 
 CNS, central nervous system; EAE, exper-
imental autoimmune encephalomyelitis; MBP, myelin basic protein; MS,
multiple sclerosis; PLP, proteolipid protein.
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hand, administration of IFN-
 
g
 
 has also been shown to
ameliorate EAE induced by antigen/adjuvant in SJL/J mice
(13). According to Steinman (14), cytokines such as IL-4
and IL-10 have a effect opposite to tolerance when given
systemically. Using a myelin basic protein (MBP)-specific
adoptive transfer system, Cannella et al. (15) not only failed
to prevent EAE by administration of IL-10 but actually
worsened its clinical course. The aforementioned discrep-
ancies are probably due to the fact that cytokines can affect
the disease process at multiple stages, from alteration of lev-
els of MHC expression to late effector functions of mac-
rophages.
We assessed the role of Th1 and Th2 cells in EAE by
transferring in vitro generated Th1 and Th2 cells from
MBP-specific TCR transgenic mice into normal and im-
munodeficient mice. Th1 cells caused EAE in all recipients
after a short preclinical phase. Surprisingly, Th2 cells also
caused EAE in RAG-1 KO mice and in 
 
ab
 
 T cell–defi-
cient mice, albeit after a longer preclinical phase. Normal
or 
 
gd
 
 T cell–deficient mice were resistant to EAE induced
by Th2 cells. Disease induction by Th1 cells was not re-
duced in any recipient by coadmininstration of Th2 cells.
These findings indicate that MBP-specific Th2 cells have
the potential to induce EAE and that disease induction by
previously activated Th1 cells cannot be prevented by nor-
mal lymphocytes nor by previously activated Th2 cells.
 
Materials and Methods
 
Mice.
 
The establishment of MBP Ac1-11–specific T cell re-
ceptor transgenic mice has been described elsewhere (16). The
mice were made by injection of C57Bl/6 zygotes and subse-
quently were crossed with B10.PL (Jackson ImmunoResearch
Labs., Inc., West Grove, PA) to incorporate the I.A
 
u
 
 restriction
element. H-2
 
u/u
 
 mice were used in all experiments. RAG-1 KO
(17), TCR-
 
a
 
 KO (18), and TCR-
 
d
 
 KO (19), originally on
129XC57Bl/6 background, were crossed to B10.PL mice and the
first generation intercrossed to obtain mice homozygous for the
mutation as well as for H-2
 
u
 
.
 
Preparation of MBP-specific Th1 and Th2 Cells.
 
Naive MBP-
specific T cells were obtained from spleens of T/R
 
1
 
 mice on a
B10.PL genetic background. Spleen cells (1
 
 3 
 
10
 
6
 
/ml) were cul-
tured in the presence of the NH
 
2
 
 terminus acetylated MBP pep-
tide (MBP Ac1-17) and 100 U/ml of IL-12 (gift of Dr. Maury
Gately, Hoffman-La Roche, Nutley, NJ) or 200 U/ml of IL-4
(PharMingen, San Diego, CA) following established procedures
(3–5). The cultures were restimulated with peptide and syngeneic
APC (no additional interleukins) on days 4 and 8.
 
Adoptive Transfer of EAE.
 
Cells were washed with PBS and
injected intravenously into recipient mice at day 11 of culture,
when 
 
.
 
90% of the cells in culture were blastic and positive for
both V
 
b
 
8.2 and CD4. EAE was graded as follows (20): level 1,
limp tail; level 2, partial hind leg paralysis; level 3, complete hind
leg paralysis; level 4, front leg weakness; level 5, moribund.
 
Cytokine Measurements.
 
The concentration of cytokines in
culture supernates was determined by ELISA using the antibodies
BVD4-1D11 and BVD6-24G2 (PharMingen) for the detection
of IL-4, antibodies JES5-2A5 and SXC-1 (PharMingen) for the
detection of IL-10, antibodies R4-6A2 and XMG1.2 (PharMin-
gen) for the detection of IFN-
 
g
 
, and Factor-test-X kit (Genzyme
Corp., Cambridge, MA) for the detection of TNF-
 
a
 
.
Cytokine mRNA expression in splenic lymphocytes and lym-
phocytes infiltrating the CNS was determined by RT-PCR.
H-2
 
u/u
 
 RAG-1 KO mice were injected with 1
 
 3 
 
10
 
7
 
 Th2 cells.
Forty days after injection, mice were anesthetized with avertin
and perfused with 100 ml of PBS containing 5 mM EDTA (PBS/
EDTA) through the left ventricle of the heart. CNS lymphocytes
were prepared by forcing the tissue through a metal sieve with a
syringe plunger, and were subsequently purified by spinning
through 38% Percoll (Pharmacia Biotech. Inc., Piscataway, NJ).
CD4-positive cells were purified by magnetic sorting with a Su-
perMACS (Miltenyi Biotec, Sunnyvale, CA) using beads directly
coupled to anti-mouse CD4 (Miltenyi Biotec). Cells were lysed
in TriReagent (MRC Inc., Cincinnati, OH) and total RNA was
prepared following the manufacturer’s instructions. RNA was re-
verse-transcribed with Superscript (GIBCO BRL, Gaithersburg,
MD) and PCR was performed using the Clontech primer pairs for
IL-4 (product size 357 bp), IFN-
 
g
 
 (product size 365 bp), and IL-10
(product size 455 bp).
 
Radiolabeling.
 
Th1 and Th2 cells (1
 
 3 
 
10
 
8
 
) were incubated
with 1 mCi of sodium chromate (DuPont-NEN, Boston, MA) in
5 ml of complete medium. After 45 min at 37
 
8
 
C the cells were
washed twice, resuspended in PBS and injected intravenously
into RAG-1 KO mice. Whole organs from PBS/EDTA perfused
mice were measured for radioactive content in a Packard gamma-
counter.
 
Immunopathology.
 
16–22 d after adoptive transfer of MBP-
specific T cells, mice were perfused as described above with the
following changes: the main perfusion was performed with 2.5%
glutaraldehyde in phosphate buffer and was preceded by a short
perfusion with 10 ml of PBS/EDTA. Tissues were postfixed in
cold 1% osmium tetroxide for 1 h, dehydrated and embedded in
epoxy resin. 1-
 
m
 
m epoxy sections were stained with toluidine
blue for light microscopy.
 
Results
 
EAE Can Be Induced in RAG-1 KO Recipients by Both
MBP-specific Th1 and Th2 Cells.
 
In this study we gener-
ated in vitro Th1 and Th2 cells expressing the transgenic
MBP-specific TCR and studied the putative pathogenic
and protective roles of these cells by adoptive transfer into
various recipient mice. CD4 T cells from spleens of T/R
 
1
 
mice were stimulated with the MBP peptide in the pres-
ence of either IL-12 to generate Th1 cells or IL-4 to gener-
ate Th2 cells (3–5). After three rounds of stimulation, cells
were harvested, washed, and injected intravenously into
RAG-1 KO mice. Culture supernatants were analyzed to
confirm the Th1 and Th2 phenotypes of the cells to be in-
jected (Fig. 1 
 
A
 
). Transfer of 5 
 
3 
 
10
 
6
 
 Th1 cells caused se-
vere EAE in 
 
.
 
90% of the recipients. Surprisingly, trans-
fer of 5
 
 3 
 
10
 
6
 
 Th2 cells also caused severe EAE in 
 
.
 
90%
of the recipient mice, although the onset of signs was de-
layed (Fig. 1 
 
B
 
). 50% of the maximum EAE score was
reached at day 6 in Th1 cell recipients and at day 16 in Th2
cell recipients. Once initial symptoms were apparent, the
speed of disease progression was the same regardless of the
length of the preclinical phase. Coadministration of Th2
cells did not slow down the rapid onset of EAE caused by
the injection of Th1 cells (Fig. 1 
 
C
 
).
 
Th2 Cell Preparations Do Not Contain Disease Causing Th1
Cells.
 
Since disease induction by Th2 cells was unex- 
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pected, we considered the possibility that the Th2 cell pop-
ulation contained some Th1 cells which were responsible
for the delayed onset of signs. If this was the case, injection
of low doses of Th1 cells should mimic the kinetics and fi-
nal incidence of EAE observed upon injection of a high
number of Th2 cells. However, this was not the case. Dis-
ease incidence fell with decreasing numbers of transferred
Th1 or Th2 cells; however, the final incidence was compa-
rable for recipients of either Th1 or Th2 cells (Fig. 1 
 
B
 
).
Thus, a small number of contaminant Th1 cells does not
explain the high incidence of EAE in recipients of 5
 
 3 
 
10
 
6
 
Th2 cells. We also considered the possibility that some Th2
cells were converted in vivo into Th1 cells. No evidence
for such a conversion was obtained when cytokine mRNA
was analyzed in extracts of spleens and brains of Th2 cell
recipients which developed the disease: CD4
 
1
 
 T cells that
were isolated from spleen and brain of Th2 cell recipients
were found to produce IL-4 mRNA but not IFN-
 
g
 
mRNA (Fig. 2). Moreover, we assessed whether we could
convert in vitro the three times-stimulated Th2 cells into a
Th1 phenotype by adding IL-12 or IFN-
 
g
 
 and observed
no conversion, thereby confirming previous findings (21–
23 and data not shown).
 
Unusually High Numbers of Polymorphonuclear Cells and
Mast Cells Accumulate in the CNS of Th2-injected Mice.
 
Fur-
ther proof that the disease observed after injection of Th2
cells was not caused by Th1 cells was obtained by histo-
pathological analysis. Although clinically it was not possible
to distinguish EAE occurring in recipients of Th2 cells
from that occurring in recipients of Th1 cells, histological
examination revealed clear differences between the two re-
cipient types. CNS samples showed a dramatic increase in
the number of polymorphonuclear cells (
 
z
 
50% of the in-
flammatory infiltrate) in the inflammatory lesions of Th2
cell recipients (Fig. 3 
 
B
 
). In contrast, Th1 cell recipients ex-
hibited a more typical mononuclear cell-dominated EAE
lesions (Fig. 3 
 
A
 
). In addition, we observed large numbers
of mast cells in the subarachnoid space of the meninges in
Th2 cell recipients, but not in Th1 cell recipients (Fig. 3
 
C
 
). Mast cells were not found in the white matter of mice
injected with either cell type.
 
Th1 and Th2 Cells Home to the CNS with Similar Kinetics.
 
One possible reason for the delayed onset of signs of EAE
in recipients of Th2 cells is that extravasation of Th2 cells
in the brain was less efficient than that of Th1 cells. To ad-
dress this possibility, we injected intravenously radiolabeled
Th1 or Th2 cells into RAG-1 KO mice and measured the
radioactivity in different tissues at 45 and 90 h after injec-
tion. No gross differences were found in the migratory pat-
tern of Th1 and Th2 cells (Fig. 4).
 
Immunocompetent Mice Are Resistant to EAE Induced by
Th2 Cells.
 
In all experiments described thus far, the MBP-
specific T cells were injected into RAG-1 KO mice. Inter-
estingly, when normal B10.PL mice were used as recipi-
ents, Th2 cells did not cause EAE, although Th1 cells
caused the fast onset disease as in the RAG-1 KO recipients
(Fig. 1 
 
D
 
). Similar to the disease induced in RAG-1 KO
recipients, Th1 cell-mediated disease in B10.PL recipients
was neither prevented nor ameliorated by coadministration
of Th2 cells (data not shown). The lack of Th2 cell-medi-
ated disease was also observed in 
 
gd
 
 T cell–deficient but
not in 
 
ab
 
 T cell–deficient recipients (Table 1).
Figure 1. (A) Interleukins in the supernatants of MBP-specific Th1 and
Th2 cultures at the day of injection. (Gray bars) Th1 cultures; (black bars)
Th2 cultures. (B) Both Th1 and Th2 anti-MBP T cells induce EAE in
RAG-1 KO recipients. Mice were injected intravenously with 5 3 106
Th1 cells (open squares, n 5 9), 5 3 106 Th2 cells (filled squares, n 5 6), 0.2 3
106 Th1 cells (open circles, n 5 5), or 0.2 3 106 Th2 cells (filled circles, n 5 3).
Data is presented as a percentage of maximum possible EAE that would
be reached if all the mice were at level 5. Animals reaching level 5 were
sacrificed and their score was kept at level 5 for the remaining of the ex-
periment. Data from one representative experiment (out of five) is shown.
(C) Coinjection of Th2 does not alter the kinetics of EAE caused by Th1
cells. RAG-1 KO recipient mice were injected intravenously with 10 3 106
Th1 cells (open squares, n 5 12), 10 3 106 Th2 cells (filled squares, n 5 12),
or a mixture of 5 3 106 Th1 cells and 5 3 106 Th2 cells (cross, n 5 4). (D)
MBP-specific Th2 cells do not induce EAE in syngeneic immunocompe-
tent recipients. Ten million Th1 cells (open symbols) or Th2 cells (filled
symbols) were injected intravenously into RAG-1 recipients (squares, n 5
12 for both Th1 or Th2 recipients) or B10.PL recipients (triangles, n 5 6
for both Th1 and Th2 recipients).
Figure 2. Th2 cells but not
Th1 cells are recovered from an-
imals to which cells from Th2
cell cultures had been injected.
Spleen (top two panels) and CNS
cells from mice injected with
Th2 cells were prepared 40 d af-
ter injection, when mice were at
level 2 and 3 of EAE. The lower
two panels show purified CD4-
positive cells. RT-PCR was per-
formed to determine mRNA
levels of IL-4, IFN-g, and IL-10.
The IFN-g mRNA present in
total splenocytes and absent in
CD4 purified splenocytes and
lymphocytes from CNS is likely
coming from NK cells.310 Autoimmune Encephalomyelitis Induced by Th2 cells
Discussion
This study has shown that MBP-specific CD4 T cells
which had been primed in vitro for IFN-g production are
capable of causing EAE upon transfer into normal or im-
munocompromised mice. Th2 cells failed to protect against
Th1 cell–mediated EAE, and caused EAE by themselves
when transferred to immunocompromised RAG-1 KO re-
cipients. There were three main differences between dis-
ease induction by Th1 and Th2 cells. First, the appearance
of first clinical signs was delayed by z10 d in Th2 cell re-
cipients as compared to Th1 cell recipients. Second, normal
(i.e., RAG-11) mice were resistant to EAE induction by
Th2 cells but not induction by Th1 cells. Third, an unusu-
ally high percentage of polymorphonuclear cells and mast
cells was present in the CNS of RAG-1 KO mice into
which Th2 cells had been transferred but this was not the
case in RAG-1 KO mice that had received Th1 cells.
The mechanisms by which Th1 and Th2 cells induce
EAE in adoptive recipient mice are unknown. Our data
suggest that the difference in the duration of the preclinical
phase is related to differences in interleukin production
rather than to differences in the extravasation of cells from
blood vessels into the brain parenchyma (Fig. 4). The cru-
cial cytokines involved in disease induction may be IFN-g
and TNF-a in Th1 recipients and TNF-a in Th2 cell re-
cipients. However, Ferber et al. recently showed that IFN-g
KO mice develop antigen-induced EAE with similar kinet-
ics and severity as normal mice (24). An alternative view is
that TNF is responsible for the inflammation caused by
both Th1 and Th2 cells. TNF-a is present not only in Th1
culture supernatants, but also in Th2 supernatants, albeit at
lower levels (Fig. 1 A). The higher amounts of TNF re-
leased by Th1 cells may cause a more rapid inflammation.
The importance of TNF in EAE induction has been
known for several years: for example, injection of anti TNF
antibodies has been shown to inhibit EAE in adoptive
transfer systems (25–26). Moreover, the encephalogenicity
of some T cell clones has been positively correlated with
the amount of TNF produced (27); in addition, a demye-
linating disease has been described in a line of TNF-a
transgenic mice in which the transgene is selectively ex-
pressed in the CNS (28).
Figure 4. Th1 cells do not migrate faster into the CNS parenchyma
than Th2 cells. Th1 (gray bars) and Th2 cells (black bars) were labeled with
51Cr and injected intravenously. After 45 and 90 h the mice were perfused
and the radioactivity of several organs was determined in a gamma
counter. At all time points most of the counts were found in the liver.
Data are presented as a ratio between counts in the CNS and counts in
the liver. One representative experiment (of three) is shown.
Table 1. Susceptibility of Different Mouse Mutants to EAE 
Induced by Th1 or Th2 MBP-specific T Cells
Injected MBP-specific T cells
Host Th1 Th2
RAG-1 KO Early onset Late onset
TCR-a KO Early onset Late onset
TCR-d KO Early onset No EAE
B10.PL Early onset No EAE
Early onset and late onset mean, respectively, that 50% of maximum
EAE score was reached before or after day 10 after injection of 106 cells
or more.
Figure 3. Unusually high numbers of polymorphonuclear cells and
mast cells are found in spinal cord lesions of Th2 cell– but not in Th1
cell–induced EAE. 1-mm thin Epoxy sections from mice with EAE (clin-
ical grade 2) injected with Th1 (A) or Th2 (B and C) MBP-specific T
cells were stained with toluidine blue. (Yellow arrows) Polymorphonuclear
cells in the white matter infiltrates. (Black arrows) Mast cells in the sub-
arachnoid space of the meninges. Original magnification: (A and B)
31,500; (C) 33,300.311 Lafaille et al.
Using Th1 and Th2 cells derived from the same precur-
sors and expressing identical MBP-specific TCR, we have
not been able to obtain any evidence supporting the com-
mon assumption that Th2 cells protect mice against Th1
cell–mediated, inflammatory diseases (7, 8). A lack of pro-
tection by antigen-specific Th2 cells was also described in a
diabetes model (29) as well as in an EAE adoptive transfer
model in which short-term polyclonal PLP-specific Th1-
enriched and Th2-enriched cultures were administered
(30). On the other hand, two reports have described pro-
tective effects of CNS-specific Th2 clones on EAE (31,
32). In these studies, disease was induced by antigen plus
adjuvant, not by adoptive transfer of activated Th1 cells. It
is possible that Th2 cells may prevent the generation of the
more pathogenic Th1 cells from naive cells, but fail to
counteract already activated Th1 cells. However, this ex-
planation is unlikely since Kuchroo et al. described protec-
tion by PLP-specific Th2 cells even when administered af-
ter the appearance of the first signs of EAE, which is clearly
too late if Th2 cells were to act by preventing the genera-
tion of Th1 cells (32). An alternative explanation is that
Th2 populations generated under different conditions or
from animals of different genetic backgrounds also differ in
some of their properties, despite commonly secreting IL-4,
IL-5, high levels of IL-10, and no IFN-g. The importance
of non–MHC–linked genes in determining a preferential
Th1 or Th2 response has been established (6, 33). It is also
possible that genetic differences account for quantitative or
qualitative differences among Th2 populations.
Our results demonstrate that MBP-specific Th2 cells
have the potential to cause EAE equivalent in morbidity to
the disease caused by Th1 cells. The finding of large num-
bers of mast cells in the meninges of animals injected with
Th2 cells is rather unusual. Some of the mast cells were
partially degranulated (for instance, Fig. 3 C, second arrow
from top). Since the recipient mice are RAG-1–deficient,
degranulation of mast cells in these animals is not mediated
by IgE. Mast cells could affect the course of EAE by several
means. Through release of histamine and other vasoactive
substances they can affect the properties of the blood-
brain-barrier, and through the action of proteases and other
mediators, they may cause myelin damage (34–36).
The potential danger of therapies based on immune de-
viation from Th1 cells towards Th2 cells has been previ-
ously appreciated by others (30, 37, 38). Th2 responses are
responsible for allergic diseases and at least one autoim-
mune condition, Omenn’s syndrome, a disease associated
with severe immunodeficiency (39). Interestingly, we ob-
served pathogenic Th2 cell effects only in association with
T cell immunodeficiency. A clear protective effect against
Th2 cell–mediated EAE was apparent when, instead of
RAG-1 KO mice, normal mice were used as recipients.
This protection depends on ab T cells since ab T cell–defi-
cient recipients, but not gd T cell–deficient recipients were
susceptible to disease induction by Th2 cells.
The role of ab T cells in the protective effect against Th2
cell–mediated EAE remains an interesting unresolved issue.
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